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ABSTRACT
CB2isaGiprotein–coupled receptor activatedbyendo-andphytocannabinoids, thus inhibitingstimulatedadenylylcyclase activity.CB2
is expressed in bone cells and Cb2 null mice show a marked age-related bone loss. CB2-specific agonists both attenuate and rescue
ovariectomy-induced bone loss. Activation of CB2 stimulates osteoblast proliferation and bone marrow derived colony-forming units
osteoblastic. Here we show that selective and nonselective CB2 agonists are mitogenic in MC3T3 E1 and newborn mouse calvarial
osteoblastic cultures.TheCB2mitogenicsignalingdependscriticallyonthestimulationofErk1/2phosphorylation anddenovosynthesis
of MAP kinase–activated protein kinase 2 (Mapkapk2) mRNA and protein. Further downstream, CB2 activation enhances CREB
transcriptional activity and cyclin D1 mRNA expression. The CB2-induced stimulation of CREB and cyclin D1 is inhibitable by pertussis
toxin, the MEK-Erk1/2 inhibitors PD098059 and U0126, and Mapkapk2 siRNA. These data demonstrate that in osteoblasts CB2 targets a
Gi protein–cyclin D1 mitogenic axis. Erk1/2 phosphorylation and Mapkapk2 protein synthesis are critical intermediates in this axis.
 2011 American Society for Bone and Mineral Research.
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Introduction
C
B2 is a seven-transmembrane domain receptor coupled to
the inhibitory guanine nucleotide-binding regulatory pro-
tein subclass of G proteins. It is activated by endo- and
phytocannabinoids, thus inhibiting stimulated adenylyl cyclase
activity.
(1,2) Unlike the neuronal CB1 cannabinoid receptor, CB2 is
expressed predominantly in nonneuronal cells and has no
psychoactivity. In bone, CB2 is expressed in osteoblasts,
osteocytes, and osteoclasts. Cb2 null mice show a marked
age-related bone loss, and CB2-specific agonists both attenuate
and rescue ovariectomy (OVX)–induced bone loss.
(3–5) Notably,
CB2 activation is mitogenic to osteoblasts in culture and
increases the number of bone marrow colony-forming units
osteoblastic.
(3) At least one of the endocannabinoids present in
bone, anadamide, stimulates osteoblast proliferation in vitro
(data not shown).
In mammalian cells, the family of mitogen-activated protein
(MAP) kinases provides a key link between membrane-bound
receptors and changes in the pattern of gene expression. The
MAP kinases are activated downstream of many different types
of receptors, including tyrosine kinase receptors, cytokine
receptors, and serpentine G protein–coupled receptors.
(6,7)
The MAP kinases consist of three subfamilies: the extracellular
signal–regulated kinases 1 and 2 (Erk1/2), c-Jun N-terminal
kinase/stress-activated kinase, and p38 MAP kinase. Further
downstream, they regulate a multitude of transcription factors
that control cell proliferation, survival, and differentiation.
(8,9) In
osteoblasts, Erk1/2-dependent phosphorylation cascades have
been implicated in the regulation of proliferation and RUNX2
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308activity.
(10–12) Activation of p38 has been demonstrated in
osteoblasts undergoing differentiation after stimulation with
bone morphogenetic protein 2 (BMP-2) and transforming
growth factor b1 (TGF-b1).
(13,14)
Downstream of Gi protein, CB2 regulates Erk1/2 and/or p38
phosphorylation. Depending on the cell type involved, this
regulation is either stimulatory or inhibitory.
(15–17) However, very
little is known about CB2-triggered signaling events further
downstreamoftheseMAPkinases.Hence,inthisstudy,weasked
which of these MAP kinase subfamilies is used by CB2 in
osteoblasts and what is the further downstream osteoblastic
pathway that communicates CB2 mitogenic signals.
Materials and Methods
Materials
PolymethylmethacrylateTechnovit9100wasfromHareusKulzer
(Wehrheim, Germany). Calcein and pertussis toxin (PTX) were
purchased from Sigma (cat. no. C-0875 and P-7208; St Louis, MO,
USA). Tissue culture ingredients were from Biological Industries
(Beit Haemek, Israel). Collagenase P was purchased from Roche
Applied Science. Antibodies to phosphorylated and nonpho-
sphorylated Erk1/2, p38 MAP kinase, and mitogen-activated
protein kinase–activated protein kinase 2 (Mapkapk2) were from
Cell Signaling Technologies (Danvers, MA, USA). The Erk1/2-
activating kinase MEK inhibitors PD098059 and U0126 and p38
MAP kinase inhibitors SB203580 and SB202190 were from
Calbiochem. Reagents for the luciferase assay were obtained
from Promega (Madison, WI, USA). siRNA materials were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Colorimetric 5-
Bromo-2-Deoxyuridine (BrdU) Labeling and Detection Kit III was
from Roche Diagnostics. Reagents for real-time RT-PCR were
from Applied Biosystems (Foster City, CA, USA). AM-1241 was
from Alexis Biochemicals. The EZ-ChIP kit was purchased from
UpstateMillipore(Billerica,MA,USA),andanti-phospho-CREB(on
serine 133) antibody was from Cell Signaling Technologies. The
Qiaquick spin kit for DNA extraction was from Qiagen.
Animals
Wild-type (WT) C57Bl/6J mice were from Harlan Israel. Cb2 null
mice
(18) were crossed for 10 generations to WT C57BL/6J mice to
generate a congenic C57BL/6J Cb2
–/– strain and further bred
under SPF conditions at the Hebrew University Ein Kerem Animal
Facility.TheeffectofCB2signalinginOVXanimalswasanalyzedin
normal C57Bl/6mice.Animalswere injected intraperitoneally with
HU-308 at 20mg/kg per day for 6 weeks, beginning 6 weeks after
OVX. The injection vehicle was ethanol/emulphor/saline (1:1:18).
Sham OVX surgery comprised exposure of the ovaries. To study
bone formation, newly formed bone was vitally labeled with the
fluorochrome calcein injected intraperitoneally (15mg/kg) 4 days
and1daybeforeeuthanization.Ateuthanization,thefemurswere
separated,fixedfor24to48hoursinphosphate-bufferedformalin,
and further kept in 70% ethanol. The experimental protocols were
approved by the Institutional Animal Care and Use Committee of
the Hebrew University of Jerusalem.
Histomorphometry
Femurs were embedded undecalcified in polymethyl methacry-
late. Longitudinal sections through the midfrontal plane were
left unstained for dynamic histomorphometry based on vital
calcein double labeling.
(19)
Cell cultures
MC3T3 E1 osteoblastic cells were maintained as reported
previously.
(20) Cells were incubated for 5 to 6 days in osteogenic
medium until subconfluence to allow for increased CB2 expres-
sion.
(3) Newborn mouse calvarial osteoblasts (NeMCOs) were
prepared from 5-day-old WT mice and Cb2 null mice by
successive collagenase digestions.
(21)
Western analysis
MC3T3 E1 cells were seeded in 10-cm dishes at 5 10
5 cells/dish
and incubated in osteogenic medium. Subconfluent cultures
were serum-starved overnight in 0.5% bovine serum albumin
containing a-MEM. Thereafter, the cells were incubated for
various time periods ranging from 5minutes to 2hours in the
same medium with or without cannabinoid ligands and
MAP kinase inhibitors. The cells then were rinsed with cold
phosphate-buffered saline and lysed with 50mM of Tris-HCl
buffer (pH 7.5), 1% Triton X-100, 150mM of NaCl, 1mM of EGTA,
50mM of b-glycerophosphate, 1mM of NaF, 10mg/mL of
leupeptin, 10mg/mL of aprotinin, 0.5mM of phenylmethylsulfo-
nyl fluoride, and 1mM of sodium orthovanadate. The cells then
were scraped off using a rubber policeman, and the lysates were
clarified by centrifugation at 12,000g for 15minutes. Samples
from each lysate, containing 40 to 120mg of protein, were frac-
tionated by SDS-PAGE and then electroblotted onto nitrocellu-
lose membranes. The membranes were blocked with nonfat dry
milk in TRIS-buffered saline/Tween-20 solution. The Western
blots were probed with antibodies to phosphorylated Erk1/2,
Erk1/2, phosphorylated p38, p38, phosphorylated Mapkapk2
(Thr222), and Mapkapk2. Proteins on the Western blots were
detected using the EZ-ECL chemiluminescent detection system
(Biological Industries).
DNA synthesis measurement
After serum starvation, the cells were incubated for 24hours in
0.5% bovine serum albumin with or without the ligands and with
or without PTX, inhibitors of MAP kinase phosphorylation, and
Mapkapk2 siRNA. This was followed by labeling with BrdU for
24hours and determination of its incorporation into DNA using a
commercial kit according to the manufacturer’s instructions.
RNA interference
Inhibition of Mapkapk2 expression was achieved using a
commercial siRNA kit according to the manufacturer’s instruc-
tions. The kit included mouse Mapkapk2 siRNA (cat. no. SC-
35856), control siRNA (cat. no. SC-37007), siRNA dilution buffer
(cat. no. SC-29527), siRNA transfection reagent (cat. no. SC-
29528), and siRNA transfection medium (cat. no. SC-36868).
Briefly, MC3T3 E1 cells were seeded in 96-well plates,
5 10
3 cells/well in 200mL of antibiotic-free medium. Cultures
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or Mapkapk2 siRNA in transfection medium containing transfec-
tion reagent. After 5hours of incubation in control and
Mapkapk2 siRNA, the cells were serum-starved for 2hours and
then challenged with HU-308.
Luciferase assay
MC3T3 E1 cells stably transfected with a luciferase construct
reporting on CREB transcriptional activity and containing three
copies of a canonical CRE (pCRE3-luc) were reported pre-
viously.
(12) To test the effect of HU-308 on CREB transcriptional
activity, the stably transfected cells, heretofore MC3T3 E1/CRE-
luc, were plated in 48-well plates and grown for 48hours in a-
MEM supplemented with 10% fetal calf serum. After 2hours of
starvation, the cells were fed with HU-308 with or without
PD098059 in a-MEM containing 0.5% bovine serum albumin.
The cells were harvested 16hours thereafter and lysed in
‘‘reporter lysis buffer’’ (Promega). Luciferase activity was
determined using a microtiter plate luminometer (LB940
Multilabel Reader, Berthold Technologies).
Real-time RT-PCR
Total RNA was isolated from MC3T3 E1 and NeMCO cells
incubated for 4hours with or without HU-308 and MAP kinase
inhibitors using the TRI Reagent Kit (Molecular Research Center,
Inc., Cincinnati, OH, USA) followed by a phenol-chloroform phase
extraction and isopropyl precipitation. RNA quality was assessed
by light absorbance at 260 and 280nm and by agarose gel
electrophoresis and ethidium bromide staining. Real-time
RT-PCR analysis for Mapkapk2 and cyclin D1 mRNA levels was
carried out by using Applied Biosystems Taqman Gene Ex-
pression Assays (respective assay IDs Mm01288465_m1 and
Mm00432359_m1). Data were normalized to b-actin (assay ID
Mm00607939_s1). Relative quantity (RQ) data were calculated as
percent maximal expression.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation assays were carried out 5hours
after a challenge with 10
 8 M HU-308 or vehicle according to the
manufacturer’s instructions. DNA was extracted and post-ChIP
RT-PCR carried out using a phospho-CREB antibody. Gels were
subjected to computerized densitometry, with negative IgG
controls being subtracted, and the values were normalized using
internal control for RNA polymerase II immunoprecipitations on
the promoter of GAPDH. Primer sequences for GAPDH were
forward, TAC TAG CGG TTT TAC GGG CG; reverse, TCG AAC AGG
AGC AGA GAG CGA. The primer sequences for cyclin D1 CRE
promoterelementwereforward,TCCCAGTTTGGAGAGAAGCA;
reverse, AGA GAT CAA AGC CGG GCA GAG AAA.
Statistical analysis
Analysis of variance was employed for statistical analysis. When
significant differences were indicated by analysis of variance,
group means were compared using the Student-Newman-Keuls
test for pairwise comparisons.
Results
We have reported previously that the CB2-specific agonist HU-
308
(22) stimulates endosteal bone formation and attenuates
OVX-induced bone loss. In this model, HU-308 did not induce an
increase in trabecular bone formation apparently because it was
already enhanced as part of the high bone turnover triggered
by OVX.
(3) However, a micro–computed tomographic (mCT)
analysis showed that daily administration of HU-308 also can
rescue OVX-induced trabecular bone loss.
(4) Because in cell
cultures CB2 activation is mitogenic to osteoblasts, and because
osteoblast number is the major determinant of bone forma-
tion,
(21) we assessed whether CB2 activation affects trabecular
bone formation in the more permissible rescue assay. Indeed,
we show here in the same femoral specimens that HU-308
stimulates trabecular and endosteal bone formation (Supple-
mental Fig. S1), providing a rationale for the in-depth analysis of
the CB2 mitogenic mechanism in osteoblasts.
To confirm that the mitogenic activity of HU-308 is shared by
other CB2 agonists, we compared its effect on DNA synthesis
with that of another specific CB2 agonist, AM-1241,
(23) and the
CB1/CB2 agonist D
9-tetrahydrocannabinol (THC).
(24) As in bone
marrow–derived and MC3T3 E1 osteoblasts,
(3) HU-308 stimu-
lated BrdU incorporation into NeMCO DNA dose-dependently,
with a maximal, greater than 2-fold effect at 10
 9 to 10
 8 M
(Fig. 1A). Analyzing AM-1241 in the same system demonstrated a
similar dose-response relationship (Fig. 1B). THC was also
mitogenic to osteoblasts, but it was markedly more potent
than the other agonists, having its peak effect at 10
 12 M (Fig.
1C). Importantly, none of the agonists was mitogenic in NeMCO
derived from CB2-deficient mice. Taken together, these data
confirm the mitogenic activity of CB2, which is independent of
the type of agonist used.
Mitogenic signals inmany cell types, including osteoblasts, are
mediated by MAP kinases regardless of the receptor class
involved, for example, tyrosine kinase or G protein–coupled
receptors.
(6,7) Furthermore, MAP kinases are also activated by
CB2-triggered signals.
(15) Hence, we tested whether in osteo-
blasts too, CB2 agonists stimulate MAP kinase phosphorylation.
Indeed, we show that prolonged challenge of MC3T3 E1
osteoblasts with optimal doses of either HU-308, AM-1241, or
THC stimulated Erk1/2 phosphorylation (Fig. 2A). A detailed
temporal analysis demonstrated that the enhancement of Erk1/2
stimulation persists at least between 5minutes and 2hours from
the time of exposure to HU-308 (Fig. 2B), suggesting that
receptor desensitization is very slow, if any. The HU-308
stimulation of BrdU incorporation into newly synthesized DNA
in MC3T3 E1 and WT NeMCO cells and the HU-308-induced
increase in the number of these cells were dose-dependently
suppressed bythe MEK-Erk1/2 pathwayinhibitors PD098059and
U0126 (Figs. 2C, D, and Supplemental Fig. S2A). Consistent with
the BrdU data (Fig. 1), CB2-deficient NeMCOs were nonrespon-
sive in this experimental setting (Fig. 2D). These results suggest
that stimulation of the Erk1/2 pathway is required for CB2
mitogenic signaling.
To rule out the possible involvement of p38 in the CB2-
trigered mitogenic signaling cascade, we analyzed p38 activa-
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phosphorylation in MC3T3 E1 osteoblasts (Fig. 3A). In addition,
SB203580 and SB202190, specific inhibitors of p38,
(25,26) did not
inhibit the HU-308 stimulation of DNA synthesis and cell number
in WT NeMCO even at 100 and 25mM, respectively (Fig. 3B and
Supplemental Figure S2B). As in the experiment with PD098059
(Fig. 2D), Cb2 null cells did not respond to either HU-308 or
inhibition of p38 (Fig. 3B).
In a previous study on Gi protein–mediated mitogenic effect in
osteoblasts, we unraveled a signaling pathway downstream of
Erk1/2 that consists of elevated Mapkapk2 mRNA levels and
stimulation of CREB.
(12) Because of the similarity between the
upstreamplayersintheearlierandthisstudy,thatis,Giproteinand
Erk1/2 stimulation, we set out to assess the use of these
downstream events by CB2. Expectedly, in MC3T3 E1 cells, an 8-
hour challenge with HU-308 stimulated Mapkapk2 mRNA levels
dose-dependently at 10
 9 to 10
 7 M (Fig. 4A). The upregulation of
Mapkapk2 mRNA triggered by CB2 activation resulted in a parallel
increaseattheprotein level(Fig. 4B). Wealsoinvestigatedwhether
the increase in the Mapkapk2 protein was associated with an
alteration in its phosphorylation state. Western analyses with
antibodies against phosphorylated Mapkapk2 yielded essentially
the same results as those obtained with the pan antibody,
suggesting that the HU-308-induced increase in Mapkapk2 protein
was not associated with alterations in its phosphorylation status
(Fig. 4B). The increases in Mapkapk2 mRNA levels were blocked by
PD098059 and U0126 (Fig. 4C and Supplemental Fig. S2C),
indicating that activation of the MEK-Erk1/2 pathway is critical for
mediatingthestimulationofMapkapk2expressioninducedbyCB2
activation. We used RNA interference to silence the Mapkapk2
gene and determine whether Mapkapk2 plays a role in CB2
mitogenic signaling. Compared with control siRNA, Mapkapk2
siRNAmitigated the stimulatory effect of HU-308 on DNAsynthesis
(Fig. 4D), indicating thatsynthesisofMapkapk2isnecessaryfor the
mitogenic signaling of CB2.
Because in osteoblasts and other cells CREB is one of the main
targets of Mapkapk2,
(12,27) we assessed the effect of HU-308 on its
transcriptional activity. The effect of HU-308 was measured in
MC3T3 E1/CRE-luc cells, which are stably transfected with a
luciferase construct that reports on CREB transcriptional activity.
Luciferase assays then were performed to functionally investigate
the transcriptional outcome after stimulation of the Gi protein–
Erk1/2–Mapkapk2 cascade. As shown in Fig. 5A, CB2 activation in
the MC3T3 E1/CRE-luc cells stimulated luciferase activity dose-
dependently, peaking at 10
 9 to 10
 8 M. The stimulation of CREB
transcriptional activity by CB2 activation was mitigated dose-
dependently by PTX (Fig. 5B), by the MEK-Erk1/2 inhibitors
PD098059 and U0126 (Fig. 5C and Supplemental Fig. S2C), and by
Mapkapk2 siRNA (Fig. 5D). Jointly, the established relationship
between Mapkapk2 and CREB, the CB2-induced activation of both
proteins, and the attenuation of the CB2-mediated CREB
transcriptional activity by PTX, MEK/Erk1/2 inhibitors PD098059
and U0126, and Mapkapk2 siRNA (Fig. 5 and Supplemental Fig. S2)
suggests that CREB is the downstream link in a CB2-activated
mitogenic signaling axis that depends on the stimulation of Erk1/2
activity and Mapkapk2 protein synthesis.
Several G protein–coupled receptors (GPCRs) control osteo-
blast proliferation through the regulation of cyclin D1 expression
by CREB.
(28) Therefore, we assessed the effect of CB2 activation
on cyclin D1 mRNA. Indeed, HU-308 stimulates osteoblastic cyclin
D1 mRNA levels, and this enhancement is inhibitable by PTX,
PD098059, U0126, and Mapkapk2 siRNA (Fig. 6A–C and
Supplemental Fig. S2D), suggesting that cyclin D1 is a mitogenic
regulator targeted by CB2. In line with these findings, HU-308
enhanced the binding of phospho-CREB to the promoter of
cyclin D1 (Fig. 6D).
Fig. 1. CB2 agonists stimulate osteoblast mitogenesis. BrdU uptake by
NeMCOs from wild-type (full squares) and Cb2
–/– mice (open squares). (A)
HU-308. (B) AM-1241. (C) THC. Data are mean SE of Treated/Control
ratio obtained in 5 culture wells per condition. Tr¼agonist-treated
cultures; Ct¼agonist-free control cultures.
ap< .05 versus Ct.
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In this study we show that downstream of Gi protein, CB2
mitogenic signaling in osteoblasts involves phosphorylation of
Erk1/2 and de novo Mapkapk2 mRNA and protein synthesis.
Further downstream, CB2 activation stimulates CREB transcrip-
tional activity and cyclin D1 expression (Fig. 7), both inhibitable
by suppressing Erk1/2 activation and Mapkapk2 protein
synthesis.
Using the WT- and Cb2
–/–-derived NeMCO model and the
selective CB2 agonists HU-308 and AM-1241,
(22,23) we confirm
here that CB2 activation is mitogenic to osteoblasts. By
comparison with these agonists, the mitogenic effect of the
CB1/CB2 agonist THC
(29) is markedly more potent. In osteoblasts,
CB1 is expressed at very low levels.
(3,30,31) Regardless of the CB1
level, the failure of THC to enhance DNA synthesis in NeMCOs
derived from Cb2 null mice suggests that osteoblastic CB1 is not
involved in proliferative activity.
Based on the reported CB2 signaling in a variety of cell types,
and because ERK1/2 and/or p38 mediate a handful of
extracellular signals in osteoblasts,
(27,32,33) we tested whether
the CB2 agonists increase the phosphorylation of these kinases.
Indeed, all three agonists potently stimulated Erk1/2 phosphor-
ylation. Moreover, this stimulation and the CB2 mitogenic action
were blocked by the specific Erk1/2 inhibitors PD098059 and
U0126, indicating that ERK1/2 activation is a critical link in the
CB2-triggered stimulation of DNA synthesis. Cellular responses
mediated by GPCRs are usually rapidly attenuated, a process
termed desensitization. By contrast, the prolonged activation of
Fig. 2. CB2 mitogenic signaling in osteoblastic cells is mediated by Erk1/2. (A,B) Stimulation of Erk1/2 phosphorylation in MC3T3 E1 cells: (A) 2-hour
challenge with selective CB2 agonists HU-308 and AM-1241 and CB1/CB2 agonist THC at 10
 8,1 0
 9, and 10
 12 M, respectively; (B) 5 to 120 minute
challenge with 10
 8 M HU-308. (C,D) Inhibition of HU-308–stimulated DNA synthesis by MEK-Erk1/2 inhibitor PD098059: (C) MC3T3 E1 cells; (D) NeMCO
cultures derived from wild-type (black bars) and Cb2
–/– animals (gray bars). Data are mean SE obtained in three culture wells per condition.
ap<.05
versus Ct.
Fig. 3. p38 is not involved in CB2 signaling in osteoblasts. (A) MC3T3 E1
osteoblastic cells were incubated with or without CB2-specific agonist
HU-308. Western blot analysis was performed with anti-phosphorylated
p38 (p-p38) or anti-p38 antibodies. (B) Cell counts in NeMCO cultures
derived from wild-type (black bars) and Cb2
–/– animals (gray bars)
incubated for 48hours with or without HU-308 and the indicated doses
ofp38phosphorylationinhibitorSB203580.Dataaremean SEobtained
in three culture wells per condition.
ap<.05.
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CB2-induced Gi protein activation is attenuated very slowly. The
rate of desensitization is regulated by phosphorylation of G
protein–coupledreceptorkinases(GRKs),which,inturn,promote
the binding of arrestins to the receptor, resulting in the
uncouplingofGPCRs fromGproteins.
(34,35)Hence, thesefindings
further suggest a specific slow-acting set of GRKs and arrestins in
use of osteoblastic CB2. Unlike Erk1/2, p38 is not stimulated by
CB2 activation, and the p38 inhibitors SB203580 and SB202190
do not affect the CB2-mediated increase in cell number. These
data strongly suggest that Erk1/2 are the only MAP kinases
involved in the CB2 mitogenic signaling.
We have noted previously that unlike the case of many other
mitogens such as platelet-derived growth factor and epidermal
growth factor, whereby stimulation of DNA synthesis is
measurable already after 24hours,
(36,37) approximately 48hours
are required before the mitogenic action of CB2 becomes
traceable.
(3) We therefore assumed that the CB2-activated
signaling cascade downstream of Erk1/2 involves de novo
mRNA and protein syntheses. A likely candidate for such a
signaling event was Mapkapk2, whose involvement in a delayed
Gi protein–mediated mitogenic signaling had been reported.
(12)
Indeed, we demonstrate that CB2 induces accumulation of
Mapkapk2 mRNA and protein and that these events are critical in
CB2 mitogenic signaling. We further show that stimulation of the
nonphosphorylated Mapkapk2 substrate is associated with a
parallel stimulation of the phosphorylated Mapkapk2 product.
The increase in activated Mapkapk2 is traceable after a several-
hour challenge with a selective CB2 agonist, in line with the
requirement for de novo protein synthesis. That Mapkapk2
protein synthesis is essential for the CB2 mitogenic activity is
demonstrated by its inhibition using Mapkapk2 siRNA. Although
Mapkapk2, also designated MK2,
(38) is generally accepted as a
substrate for p38,
(39,40) it was identified originally as an Erk
target.
(41) Furthermore, PD098059 partially inhibits the activation
of Mapkapk2 by the GPCR agonist endothelin 1.
(42) Although it is
Fig. 4. Stimulation of Mapkapk2 mRNA and protein downstream of Erk1/2 is essential for CB2 mitogenic signaling in osteoblasts. (A–C) MC3T3 E1 cells
were challenged with HU-308 for 8hours: (A) dose-response analysis of Mapkapk2 mRNA levels analyzed by real-time PCR; (B) Western blot analysis with
antibodies against Mapkapk2 or phosphorylated Mapkapk2; (C) Cells were incubated with HU-308 with or without the MEK-Erk1/2 inhibitor PD098059.
(D) Inhibition of CB2 mitogenic signaling in MC3T3 E1 cells by siRNA to Mapkapk2. Quantitative data are mean SE obtained in six culture dishes per
condition.
ap<.05 versus Ct or cultures treated with HU-308 and Ct siRNA.
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depends on de novo protein synthesis, it is suggested by several
instances where prolonged challenging was required for its
activation.
(43,44) That the CB2 stimulation of Mapkapk2 synthesis
and phosphorylation depends on Erk1/2 activation is shown by
its complete arrest with PD098059 and U0126.
CREB is one of the best characterized stimulus-induced
transcription factors. It activates transcription of target genes in
response to a diverse array of stimuli, including peptide
hormones and growth factors that activate a variety of protein
kinases.
(45) In osteoblastic cells, CREB is activated by extracellular
stimuli, including parathyroid hormone (PTH), epidermal growth
Fig. 5. CB2 mitogenic signaling in osteoblasts involves stimulation of CREB transcriptional activity downstream of enhanced de novo Mapkapk2 mRNA
levels. MC3T3 E1/CRE-luc cells were challenged with HU-308 for 8hours (A–C) or 5hours (D), and optical density was measured as luciferase relative light
units (RLUs). (A) Dose-response analysis. (B–D) Arrest of CB2-stimulated CREB activity by: (B) selective Gi protein inhibitor pertusis toxin; (C) MEK-Erk1/2
inhibitor PD098059; (D) Mapkapk2 siRNA. Data are mean SE obtained in six culture dishes per condition.
ap<.05 versus Ct or cultures treated with HU-
308 and Ct siRNA.
Fig. 6. CB2 mitogenic signaling in osteoblasts involves stimulation of cyclin D1 mRNA expression. MC3T3 E1 cells were incubated with HU-308 with or
without the following inhibitors: (A) pertussis toxin (PTX), (B) MEK-Erk1/2 inhibitor PD098059, or (C) Mapkapk2 siRNA. (D) Chromatin immunoprecipitation
analysis assay of phospho-CREB (pCREB) binding to CRE in cyclin D1 promoter. Data in panels A to C are mean SE obtained in six culture dishes per
condition.
ap<.05 versus Ct.
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(13,46,47) Morerelevant tothisstudyis
the Gi protein–Erk1/2-Mapkapk2-CREB mitogenic pathway
triggered by the osteogenic growth peptide.
(12) We show here
that this pathway communicates to the nucleus signals elicited
by CB2 agonists. The cyclin D1 promoter has a CRE consensus
sequence, rendering this transcription factor a major target for
GPCR-CREB mitogenic signaling.
(48) CREB-induced upregulation
of cyclin D1 has been implicated recently in the PTH mitogenic
effects in osteoblasts.
(49) Downregulation of CREB transcriptional
activity has been portrayed in the restrain of osteoblast
proliferation and bone formation that follows activation of the
Htr1b serotonin receptor.
(28) The inverse activity of these GPCRs,
including the present CB2 stimulation of Mapkapk2, CREB, cyclin
D1, and DNA synthesis, suggests that the Gi protein–cyclin D1
axis transmits dose-related mitogenic signals in osteoblasts.
This study confirms that Erk1/2 phosphorylation and Map-
kapk2 protein synthesis are critical for the Gi protein–cyclin D1
mitogenic axis in osteoblasts. These results in osteoblastic cells
suggest further studies to assess the in vivo significance of this
axis in the skeleton and other tissues alike.
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